Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640862 | 0.91 | MEN1 (0.39) | CTSSDRD2DPP4DPP8DPP9 | |
| SCHEMBL13641038 | 0.91 | CTSS (0.35) | CTSSDRD2DPP4DPP8DPP9 | |
| SCHEMBL13640779 | 0.90 | AXL (0.37) | CTSSDRD2DPP4DPP8DPP9 | |
| SCHEMBL13640717 | 0.90 | CTSS (0.35) | CTSSDRD2AXLMERTK | |
| SCHEMBL13640872 | 0.90 | CTSS (0.39) | CTSSDRD2DPP4DPP8DPP9 | |
| SCHEMBL13640843 | 0.87 | IDO1 (0.35) | CTSSDRD2AXLMERTK | |
| SCHEMBL13640948 | 0.85 | CTSS (0.39) | CTSSDRD2DPP4DPP8DPP9 | |
| SCHEMBL13641044 | 0.85 | CTSS (0.39) | CTSSDRD2DPP4DPP8DPP9 | |
| SCHEMBL13641092 | 0.85 | CTSS (0.37) | CTSSDRD2DPP4DPP8DPP9 | |
| SCHEMBL13641052 | 0.85 | IDO1 (0.34) | CTSSDRD2DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | CTSS 3839/4885DRD2 491/4885DPP4 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.